When everyone else is panicking, it’s time to swoop in and pick up some undervalued assets.

Easy enough in theory, but in practice it takes some work to determine what’s an undervalued asset and what’s the contemporary equivalent of Confederate money. The stock of a randomly selected social gaming company, whose products are ultimately of limited utility, might likely fall in the latter category. The stock of a biotechnology company that provides, or might one day provide, vital benefits to humanity is a different investment altogether. With the NASDAQ Biotechnology Index now off 18.5% from its latest zenith, some of the stocks whose price movements have contributed to that decline are ripe for the shrewd and opportunistic investor.

The NASDAQ Biotechnology Index (Nasdaq:NBI) tracks the movements of the stocks of 121 companies, each of which has a market capitalization of at least $200 million (among other criteria.) However, unlike the Dow Jones Industrial Average or other principal indices, the NASDAQ biotech index is weighted. Its top nine components make up most of the index’s value.

Musical Chairs

In the last few weeks, the biotech industry has been one of the most dynamic in the market, undergoing so many asset sales and takeover attempts that you need a scorecard and several pencils to keep track of the movements. Montreal’s Valeant Pharmaceuticals International (NYSE:VRX) made a hostile bid for Irvine, Calif.'s Allergan Inc. (NYSE:AGN). New York’s Pfizer Inc. (NYSE:PFE) made a similar overture to London-based AstraZeneca plc (NYSE:AZN). Meanwhile, Basel, Switzerland-based Novartis International AG (NYSE:NVS) swapped its vaccine operations (along with billions in cash) for Brentford, England-based GlaxoSmithKline plc’s (NYSE:GSK) cancer business. Once everything settles and we have some stability, to the extent that the market is ever stable, expect fewer players wielding greater influence than ever before in this growing sector.

One company that’s emerged to possibly thwart a takeover is Thousand Oaks, Calif.-based Amgen Inc. (Nasdaq:AMGN), a maker of some serious pharmaceuticals that you should consider yourself fortunate to never receive a prescription for. These include Enbrel, a rheumatoid arthritis drug that runs about $2,700 per month; and Neulasta, a white blood cell stimulant for leukemia patients that makes Enbrel look like a bargain.

Amgen stock has remained somewhat consistent for the last three quarters, and at least one analyst thinks the company could best Pfizer’s offer for AstraZeneca. That would be a fitting next stage to Amgen’s and AstraZeneca’s two-year-old agreement to jointly develop drugs that fight everything from colitis to lupus.

Amgen Undervalued?

But is Amgen stock an undervalued asset? The company is the second-largest component of the NASDAQ biotech index, comprising approximately 8% of its value. The stock trades at about 17 times earnings, which is not only low for its industry but low for Amgen’s ability to earn. Profit margins were 27% last year, this in a business where large research and development expenses are part of the game. Dividend payouts are generous, making the company’s only true negative metric being its inability to meet Wall Street forecasts. For a certain type of investor, there’s nothing remotely negative about that.

Foster City, Calif.-based Gilead Sciences Inc. (Nasdaq:GILD) is the NASDAQ biotech index’s third-largest component, and its second-largest with fundamentals that bear at least a superficial similarity to Amgen’s. Gilead initially gained fame for its HIV/AIDS drugs, and expanded into hepatitis C therapy in 2011. The company did the latter by acquisition, with unmistakable results.

Last month, the newly fortified Gilead brought a phenomenally effective hepatitis C drug to market, one so groundbreaking that the U.S. Food and Drug Administration fast-tracked it. The drug, Sovaldi, treats patients over a three-month period, which is considerably shorter than the industry standard for hepatitis C regimens. Three months’ worth of Sovaldi costs $84,000. Some insurers balk at the price tag, but Gilead’s margins on Sovaldi are merely high, not extortionate. They contribute to an overall company profit margin of around 27%, which is actually down from 33% a couple of years ago but still the envy of most every established company on the exchange. Down off its late-February zenith, Gilead currently trades in the high 70s, allowing considerable room to reach the consensus one-year target estimate that’s knocking on the door of three digits, which would be a all-time high for the company.

The Bottom Line

Nothing offers guaranteed appreciation. But at least you can invest in something whose indicators appear to indicate an eventual gain. With the recent pullback in shares, a few of the NASDAQ biotech index's components appear to be capable of making today’s buyers very happy.

Related Articles
  1. Chart Advisor

    Biotechnology Stocks To Keep on the Radar

    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  2. Investing

    The Rise of Corporate Venture Capital

    After the success of Google Ventures, corporate venture capital is an increasingly popular diversification and hedging tool for many large corporations.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  4. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Products

    Learn more about the BioShares Biotechnology Products fund, an exchange-traded fund that is focused on producers of FDA-approved drugs.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraShort Nasdaq Biotech

    Learn more about an innovative inverse-leveraged sector exchange-traded fund, or ETF, the ProShares UltraShort Nasdaq Biotechnology fund.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
  9. Stock Analysis

    Healthcare M&A and Prescription Drug Prices

    Learn how mergers among health care insurance companies and drug companies could lead to increased premiums for consumers and lower drug costs.
  10. Professionals

    How to Help Clients Spooked by Volatility

    Volatility spooks investors leading them to confuse it with risk. Here are ways to help guide your clients through times of volatility in the market.
  1. Securities-Based Lending

    The practice of making loans using securities as collateral. ...
  2. Phenotype

    An organism’s observable characteristics or traits.
  3. Pharmacology

    The study of how drugs affect people. More formally, pharmacology ...
  4. Molecular Biology

    The study of biology and biological processes at the fundamental ...
  5. Genomics

    The study of the genome, which is the complete set of the genetic ...
  6. Genetic Engineering

    The artificial modification of an organism’s genetic composition. ...
  1. How does the role of Medicare/Medicaid affect the drugs sector in the U.S.?

    Medicare and Medicaid have enormous influence on the pharmaceutical, or drugs, sector in the United States. For instance, ... Read Full Answer >>
  2. What factors make the drug sector good for value investing?

    The drugs sector is a good choice for value investing because it always has demand and a competitive moat. This simplifies ... Read Full Answer >>
  3. What annual return could an investor expect on average from the drug sector?

    The drugs sector consists of a diverse group of companies of different sizes in terms of market cap, revenues, profitability ... Read Full Answer >>
  4. What are the primary factors that drive share prices in the drugs sector?

    The primary factors that drive share prices in the drugs sector are mergers and acquisitions activity, spending on health ... Read Full Answer >>
  5. How does the profit margin compare for a generic drug versus a brand name drug?

    Profit margins are higher for generic drugs compared to brand-name drugs. However, total profits on brand-name drugs are ... Read Full Answer >>
  6. What level of return on equity is average for a company in the drugs sector?

    The drugs sector provides a variety of investing opportunities ranging from major drug manufacturing companies to generic ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!